Novo Nordisk to slash US insulin prices, following move by Eli Lilly
By Patrick Wingrove and Bhanvi Satija (Reuters) – Novo Nordisk said on Tuesday it would cut U.S. list prices for several insulin products by up to 75% next year, joining rival Eli Lilly and Co as political pressure mounts to make these life-sustaining diabetes treatments more affordable. The moves follow the passing of President Joe …
Novo Nordisk to slash US insulin prices, following move by Eli Lilly Read More »










